Dr. Tony Mok, President of IASLC, offers an overview on most common toxicities related to targeted therapies in NSCLC.
ELCC 2014: Cabazitaxel Fails to Meet the Primary Endpoint in a Randomised Phase II Study in SCLC Patients
Cabazitaxel failed to meet a primary endpoint of showing superior progression-free survival (PFS) and additionally showed less favourable median overall survival (OS) compared to topotecan in an international, randomised open-label phase II trial performed in patients with small-cell lung cancer (SCLC), who had progressed during or after first-line platinum-based chemotherapy
ELCC 2014: Clinical Utility of miRNA Signature in Plasma of Smokers Included in LD-CT Lung Cancer Screening
A group of researchers from Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, retrospectively evaluated a non-invasive plasma miRNA signature classifier in prospectively collected samples from smokers within the randomised Multicentre Italian Lung Detection (MILD) trial.
CO-1686 has demonstrated a good tolerability and promising efficacy against T790M+ epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC).
In a large number of samples of lung adenocarcinoma the incidence of RET fusion, as detected by routine diagnostics, was higher than expected, according to a report by Dr Oliver Gautschi of the Clinic for Oncology, Kantonsspital, Luzern, Switzerland.
A group of Italian and Swiss researchers have found a correlation between PD-L1 expression and EGFR mutation, as well as between PD-1 expression and KRAS mutations in a cohort of molecularly selected patients with non-small-cell lung cancer (NSCLC).